MOPP
Checked 2026-09-09
Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD
One cycle
every 28 days × 6 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Mechlorethamine Alkylating agent (nitrogen mustard); intravenous and topical gel | 6 mg/m² | IV | D1, 8 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² | IV | D1, 8 | |
Procarbazine Alkylating-like methylhydrazine derivative | 100 mg/m² once daily | Oral | D1-14 | |
Prednisone Glucocorticoid | 40 mg/m² once daily | Oral | D1-14 |
Cycles
6
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- Proof that combination chemotherapy could cure an advanced cancer; abandoned because of infertility and secondary leukaemia, which ABVD largely avoids.
Used in
Source
DeVita, Annals of Internal Medicine 1970: combination chemotherapy in advanced Hodgkin's disease
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
ICE
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
every 14 days × 2-3
Escalated BEACOPP
Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles
every 21 days × 4-6